Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Ankyra Therapeutics, IncINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | withdrawn | Phase 1 / Phase 2 | 0 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | withdrawn | Phase 1 / Phase 2 | 0 | Institut de Recherches Internationales ServierOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT05879484 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | withdrawn | Phase 1 | 0 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | withdrawn | Phase 1 | 0 | Baptist Health South FloridaOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03652233 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jun 20, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity(PRIMED-001) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) | withdrawn | Phase 1 | 0 | British Columbia Cancer AgencyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 21, 2016 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01728480 | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 11, 2013 | clinicaltrials |
| NCT01491139 | Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck(ORCA) | withdrawn | Phase 1 | 0 | University College, LondonOTHER | 0 | May 30, 2012 | clinicaltrials |
| NCT00937300 | T-cell Based Immunotherapy for Head and Neck Cancer | withdrawn | Phase 1 | 0 | Inge Marie SvaneOTHER | 1 | Nov 23, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2026source: clinicaltrials